Overview

A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)

Status:
COMPLETED
Trial end date:
2021-03-23
Target enrollment:
Participant gender:
Summary
This is a single-dose study to assess the effect of mild or moderate Hepatic Impairment (HI) on the Pharmacokinetics (PK) of rilzabrutinib as well as to evaluate the safety and tolerability of rilzabrutinib in subjects with HI.
Phase:
PHASE1
Details
Lead Sponsor:
Principia Biopharma, a Sanofi Company